Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, ...

Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Phase III program in food allergy (FA) planned for H2 2026 ...

Novartis AG (NYSE:NVS) on Thursday unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. over the next five years. The move is part of a ...

In the real-world, Pluvicto showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal-world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead ...

Novartis is building the future of leading healthcare support, from a new radioligand therapy site to a state-of-the-art research centre ...